Documente Academic
Documente Profesional
Documente Cultură
G14. &itt $, Aanna# /, "emme ?7, Co#; ", Ca'taine %, &ere- %, et al.
The e::e(t o: 'pironola(tone on morbi#it; an# mortalit; in patient'
Dith 'e*ere heart :ailure. "an#omi-e# %l#a(tone E*aluation Stu#;
In*e'ti- ator'. 0 Enl 7 Me# 1444I 3G11H04ZH1H.
G20. Aanna# /, M(Murra; 77, =rum <, *an Vel#hui'en D7, SDe#ber =,
Shi <, et al., EM&<%SIS-</ Stu#; Group. Eplerenone in patient'
Dith ';'toli( heart :ailure an# mil# ';mptom'. 0 Enl 7 Me# 2011I
35G111Z
21.
G21. Ver#e((hia &, "ebol#i G, %neli /, Gattobiio ", $enti*olio M,
Thi>' ., et al. %nioten'in-Con*ertin En-;me Inhibitor'an#
Cal(ium Channel $lo(9er' :or Coronar; <eart Di'ea'e an# Stro9e
&re*ention. <;perten'ion 2002I G51335Z342.
G22. Aan(hetti %. Cal(ium (hannel blo(9er' in h;perten'ion. In1 $la(9
<", Elliott ?7, e#itor'. <;perten'ion, a (ompanion to $raunDal#
<eart Di'ea'e. El'e*ierI 2012I (hapt 22120GZ213.
G23. Dalho: $, Se*er &S, &oulter 0", ?e#el <, $ee*er' DG, aul:iel# M,
et al. &re*ention o: (ar#io*a'(ular e*ent' Dith an antih;perten'i*e
rei- men o: amlo#ipine a##in perin#oprila' rehuire# *'. atenolol
a##in ben#ro:lumethia-i#e a' rehuire# in the %nlo-S(an#ina*ian
Car#i- a( )ut(ome' Trial-$loo# &re''ure .oDerin %rm
B%SC)T$&.%C a multi(entre ran#omi'e# (ontrolle# trial. .an(et
2002I 3551342Z405.
G2G. Strau'' M<, <all %S. Do anioten'in re(eptor blo(9er' in(rea'e
the ri'9 o: m;o(ar#ial in:ar(tionV1 %nioten'in "e(eptor $lo(9er'
Ma; in(rea'e ri'9 o: M;o(ar#ial In:ar(tion1 Mnra*elin the %"$-MI
&ara- #o6. Cir(ulation 2005I 11G1333Z32G.
G22. Sipahi I, Debanne SM, "oDlan# DO, Simon DI, /an 7C.
%nioten'in re(eptor blo(9a#e an# ri'9 o: (an(er1 meta-anal;'i' o:
ran#omi'e# (ontrolle# trial'. The .an(et )n(olo; 2010I 11152HZ
535.
G25. %"$ Triali't' (ollaboration. E::e(t' o: telmi'artan, irbe'artan,
*al'ar- tan, (an#e'artan an# lo'artan on (an(er' in 12 trial' enrollin
133 H54 in#i*i#ual'. 7 <;perten' 2011I 241523Z532.
G2H. Volpe M, %-i-i M, Dan'er %<, 0u;en G, "uilope .M. TDi'tin
arm' to anioten'in re(eptor blo(9er'Eantaoni't'1 the turn o:
(an(er. Eur <eart 7 2011I 32114Z22.
G23. Gra#man %<, S(hmie#er "E, .in' "., 0u''berer 7, Chian O,
$e- #iian M&. %li'9iren, a no*el orall; e::e(ti*e renin inhibitor,
pro*i#e' #o'e-#epen#ent antih;perten'i*e e::i(a(; an# pla(ebo-li9e
tolerabi- lit; in h;perten'i*e patient'. Cir(ulation 2002I 11111012Z
1013.
G24. )U$rien E, $arton 7, 0u''berer 7, Mul(ah; D, 7en'en C, Di(9er &,
Stanton %. %li'9iren re#u(e' bloo# pre''ure an# 'uppre''e' pla'ma
renin a(ti*it; in (ombination Dith a thia-i#e #iureti(, an anioten-
'in(on*ertin en-;me inhibitor, or an anioten'in re(eptor blo(9er.
<;perten'ion 200HI G412H5Z23G.
G30. .ittle>ohn T? 3r#, Tren9Dal#er &, <ollan#er' G, Ahao O, .iao
?.
.on-term 'a:et;, tolerabilit; an# e::i(a(; o: (ombination
therap; Dith ali'9iren an# amlo#ipine in patient' Dith
h;perten'ion. Curr Me# "e' )pin 2004I 221421Z424.
G31. &ar*in <<, &er''on /, .eDi' 7$, .eDi' E7, <ollenber 0=.
%li'9iren (ombine# Dith lo'artan in t;pe 2 #iabete' an#
nephropath;. 0 Enl 7 Me# 2003I 32312G33Z2GG5.
G32. See# %, Gar#ner ", M(Murra; 7, <illier C, Mur#o(h D, Ma(
/a#;en ", et al. 0eurohumoral e::e(t' o: the neD orall; a(ti*e renin
inhibitor, ali'9iren, in (hroni( heart :ailure. Eur> <eart /ail 200HI
411120Z 112H.
G33. &ar*in <<, $renner $M, M(Murra; 77V, #e AeeuD D, <a::er
SM, Solomon SD. Car#iorenal en#point' in a trial o: ali'9iren :or
t;pe 2 #iabete'. 0 Enl 7 Me# 2012I 35H1220GZ2213.
G3G. Gheorhia#e M, $ohm M, Greene S7, /onaroD GC, .eDi' E/,
Aanna# /, et al., :or the %ST")0%MT In*e'tiator' an# Co-
or#inator'. E::e(t o: %li'9iren on &o't#i'(hare Mortalit; an# <eart
/ailure "ea#mi''i- on' %mon &atient' <o'pitali-e# :or <eart
/ailure. The %ST")0%- MT "an#omi-e# Trial. 7%M% 2013I
30411122Z1132.
G32. "othDell &M, <oDar# SC, Dolan E, )U$rien E, Dob'on 7E,
Dahlo: $, et al. &rono'ti( 'ini:i(an(e o: *i'it-to-*i'it *ariabilit;,
ma6imum ';'toli( bloo# pre''ure an# epi'o#i( h;perten'ion.
.an(et 2010I 3H21
342Z
402.
G35. Man(ia G, Me''erli /, $a9ri' G, Ahou [, Champion %, &epine
C7.
$loo# pre''ure (ontrol an# impro*e# (ar#io*a'(ular out(ome' in
the
International Verapamil S"-Tran#olapril Stu#;. <;perten'ion
200HI
201244Z
302.
G3H. Man(ia G, /a((hetti ", &arati G, Aan(hetti %. Vi'it-to-Vi'it $loo#
&re''ure Variabilit;, Caroti# %thero'(lero'i' an# Car#io*a'(ular
E*ent' in the European .a(i#ipine Stu#; on %thero'(lero'i'. Cir(ula-
tion 2012I 1251254Z2H3.
G33. "othDell &M, <oDar# SC, Dolan E, )U$rien E, Dob'on 7E, Dahlo:
$, et al. E::e(t' o: beta blo(9er' an# (al(ium-(hannel blo(9er' on Di-
thinin#i*i#ual *ariabilit; in bloo# pre''ure an# ri'9 o: 'tro9e. .an(et
0eurolo; 2010I 41G54ZG30.
G34. ?ebb %7, /i'(her M, Mehta A, "othDell &M. E::e(t' o: antih;perten-
'i*e- #ru (la'' on inter-in#i*i#ual *ariation in bloo# pre''ure an#
ri'9 o: 'tro9e1 a ';'temati( re*ieD an# meta-anal;'i'. .an(et 2010I
3H21405Z412.
GG0. ?ebb %7, "othDell &M. E::e(t o: #o'e an# (ombination o: antih;per-
ten'i*e' on inter-in#i*i#ual bloo# pre''ure *ariabilit;1 a ';'temati(
re*ieD. Stro9e 2011I G212350Z2352.
GG1. Man(ia G, /a((hetti ", &arati G, Aan(hetti %. Vi'it-to-*i'it bloo#
pre- ''ure *ariabilit; in the European .a(i#ipine Stu#; on
%thero'(lero'i'1 metho#oloi(al a'pe(t' an# e::e(t' o:
antih;perten'i*e treatment. 7 <;perten' 2012I 30112G1Z1221.
GG2. Aan(hetti %. ?ar', Dar ame' an# #ea# bo#ie' on the battle:iel#1
*ariation' on the theme o: bloo# pre''ure *ariabilit;. Stro9e 2011I
G212H22Z2H2G.
GG3. Man(ia G, Aan(hetti %. Choi(e o: antih;perten'i*e #ru' in the Eu-
ropean So(iet; o: <;perten'ion-European So(iet; o: Car#iolo; ui-
#eline'1 'pe(i:i( in#i(ation' rather than ran9in :or eneral u'ae. 7
<;perten' 2003I 25115GZ153.
GGG. $loo# &re''ure .oDerin Treatment Triali't'U Collaboration. E::e(t'
o: #i::erent reimen' to loDer bloo# pre''ure on ma>or
(ar#io*a'(ular e*ent' in ol#er an# ;ouner a#ult'1 meta-anal;'i' o:
ran#omi'e# tri- al'. $M7 2003I 33511121Z1123.
GG2. $loo# &re''ure .oDerin Treatment Triali't'U Collaboration. Do men
an# Domen re'pon# #i::erentl; to bloo# pre''ure-loDerin treat-
mentV "e'ult' o: pro'pe(ti*el; #e'ine# o*er*ieD' o: ran#omi-e#
trial'. Eur <eart > 2003I 2412554Z2530.
GG5. ?al# DS, .aD M, Morri' 7=, $e'tDi(9 7&, ?al# 07. Combination
the- rap; *'. monotherap; in re#u(in bloo# pre''ure1 meta-
anal;'i' on
11 000 parti(ipant' :rom G2 trial'. %m 7Me# 2004I 1221240Z
300.
GGH. Corrao G, &aro#i %, Aambon %, <eiman /, /ilippi %, Cri(elli C, et
al.
"e#u(e# #i'(ontinuation o: antih;perten'i*e treatment b; tDo-#ru
(ombination a' :ir't 'tep. E*i#en(e :rom #ail; li:e pra(ti(e. 7
<;per- ten' 2010I 231123GZ1240.
GG3. %..<%T o::i(er' an# (o-or#inator' :or the %..<%T
Collaborati*e "e'ear(h Group. Ma>or out(ome' in hih-ri'9
h;perten'i*e patient' ran#omi-e# to anioten'in-(on*ertin
en-;me inhibitor or (al(ium (hannel blo(9er *' #iureti(1 The
%ntih;perten'i*e an# .ipi#-.oDe- rin Treatment to &re*ent <eart
%tta(9 Trial B%..<%TC. 7%M% 2002I
23312431Z244H.
GG4. S<E& Co-operati*e "e'ear(h Group. &re*ention o: 'tro9e b; anti-
h;perten'i*e #ru treatment in ol#er per'on' Dith i'olate# ';'toli(
h;perten'ion. /inal re'ult' o: the S;'toli( <;perten'ion in the
El#erl; &roram BS<E&C. 7%M% 1441I 25213222Z325G.
G20. .ithell <, <an''on ., S9oo I, Elm:el#t D, <o:man %, )lo:''on $,
et al. The Stu#; on Conition an# &rono'i' in the El#erl;
BSC)&EC1 prin(ipal re'ult' o: a ran#omi-e# #ouble-blin#
inter*ention trial. 7 <;perten' 2003I 2113H2Z335.
G21. Stae''en 7%, /aar# ", Thi>' ., Celi' <, %rabi#-e GG, $ir9enhaer
?<, et al. "an#omi'e# #ouble-blin# (ompari'on o: pla(ebo an# a(-
ti*e treatment :or ol#er patient' Dith i'olate# ';'toli( h;perten'ion.
The S;'toli( <;perten'ion in Europe BS;'t-EurC Trial
In*e'tiator'. .an(et 144HI 3201H2HZH5G.
G22. .iu ., ?an 7G, Gon ., .iu G, Stae''en 7%. Compari'on o:
a(ti*e treatment an# pla(ebo in ol#er Chine'e patient' Dith i'olate#
';'toli( h;perten'ion. S;'toli( <;perten'ion in China BS;'t-ChinaC
Collabo- rati*e Group. 7 <;perten' 1443I 1511323Z1324.
G23. Coope 7, ?arren#er TS. "an#omi'e# trial o: treatment o:
h;perten'i- on in el#erl; patient' in primar; (are. $M7 1435I
243111G2Z1121.
G2G. Dahlo: $, .in#holm .<, <an''on ., S(her'ten $, E9bom T,
?e'ter &). Morbi#it; an# mortalit; in the SDe#i'h Trial in )l#
&atient' Dith <;perten'ion BST)&-<;perten'ionC. .an(et 1441I
33311231Z1232.